KUKJEON PHARMACEUTICAL Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	136,468	121,998	103,711	85,354
Other Revenue	-0	-	-	-0
Revenue	136,468	121,998	103,711	85,354
Revenue Growth (YoY)	11.86%	17.63%	21.51%	-
Cost of Revenue	114,594	96,721	84,195	67,409
Gross Profit	21,874	25,277	19,515	17,946
Selling, General & Admin	15,327	12,817	11,451	8,699
Research & Development	4,684	4,821	3,981	2,651
Operating Expenses	21,507	18,768	16,027	11,836
Operating Income	366.71	6,509	3,488	6,109
Interest Expense	-8,220	-5,735	-1,802	-284.47
Interest & Investment Income	878.98	1,591	1,037	208.91
Earnings From Equity Investments	-57.48	1.15	301.09	-
Currency Exchange Gain (Loss)	-1,655	-253.67	-1,215	-869.65
Other Non Operating Income (Expenses)	10,498	-391.28	9,279	196.4
EBT Excluding Unusual Items	1,811	1,722	11,089	5,360
Gain (Loss) on Sale of Investments	1,831	16.28	67.84	-275.98
Gain (Loss) on Sale of Assets	-57.43	-	-69.18	-0
Other Unusual Items	-2,706	-	-	-
Pretax Income	879.32	1,738	11,088	5,084
Income Tax Expense	341.65	-2,954	2,210	1,046
Earnings From Continuing Operations	537.67	4,692	8,877	4,038
Minority Interest in Earnings	1,199	132	70.7	-
Net Income	1,736	4,824	8,948	4,038
Net Income to Common	1,736	4,824	8,948	4,038
Net Income Growth	-64.01%	-46.09%	121.59%	-
Shares Outstanding (Basic)	49	49	49	44
Shares Outstanding (Diluted)	49	49	51	44
Shares Change (YoY)	-	-4.23%	16.16%	-
EPS (Basic)	35.38	98.31	182.35	91.54
EPS (Diluted)	35.38	98.31	11.35	91.00
EPS Growth	-64.01%	766.11%	-87.53%	-
Free Cash Flow	2,169	-44,269	-29,304	-7,367
Free Cash Flow Per Share	44.20	-902.17	-571.94	-167.01
Dividend Per Share	10.000	-	-	-
Gross Margin	16.03%	20.72%	18.82%	21.02%
Operating Margin	0.27%	5.33%	3.36%	7.16%
Profit Margin	1.27%	3.95%	8.63%	4.73%
Free Cash Flow Margin	1.59%	-36.29%	-28.26%	-8.63%
EBITDA	5,472	9,643	4,932	7,215
EBITDA Margin	4.01%	7.90%	4.75%	8.45%
D&A For EBITDA	5,105	3,134	1,444	1,106
EBIT	366.71	6,509	3,488	6,109
EBIT Margin	0.27%	5.33%	3.36%	7.16%
Effective Tax Rate	38.85%	-	19.94%	20.58%

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.